Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

NCT03994393 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT03994393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03994393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)
Lead sponsor
University of Sydney
Phase
Phase 2
Overall status
Unknown status
Start date
October 23, 2018
Completion date
January 31, 2024
Enrollment
100 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutant advanced non small cell lung cancer